Literature DB >> 29079014

Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.

Simone Bertini1, Andrea Chicca2, Francesca Gado1, Chiara Arena1, Daniela Nieri2, Maria Digiacomo1, Giuseppe Saccomanni1, Pingwei Zhao3, Mary E Abood3, Marco Macchia1, Jürg Gertsch2, Clementina Manera4.   

Abstract

In this work, we explored the molecular framework of the known CB1R allosteric modulator PSNCBAM-1 with the aim to generate new bioactive analogs and to deepen the structure-activity relationships of this type of compounds. In particular, the introduction of a NH group between the pyridine ring and the phenyl nucleus generated the amino-phenyl-urea derivative SN15b that behaved as a positive allosteric modulator (PAM), increasing the CB1R binding affinity of the orthosteric ligand CP55,940. The functional activity was evaluated using serum response element (SRE) assay, which assesses the CB1R-dependent activation of the MAPK/ERK signaling pathway. SN15b and the biphenyl-urea analog SC4a significantly inhibited the response produced by CP55,940 in the low µM range, thus behaving as negative allosteric modulators (NAMs). The new derivatives presented here provide further insights about the modulation of CB1R binding and functional activity by allosteric ligands.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allosteric modulator; CB1 receptor; Endocannabinoid system; MAPK/ERK signaling pathway; Serum response element

Mesh:

Substances:

Year:  2017        PMID: 29079014      PMCID: PMC5794004          DOI: 10.1016/j.bmc.2017.10.015

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  45 in total

1.  Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum.

Authors:  Xiaowei Wang; James G Horswill; Benjamin J Whalley; Gary J Stephens
Journal:  Mol Pharmacol       Date:  2010-12-28       Impact factor: 4.436

Review 2.  Cannabinoid receptors as therapeutic targets.

Authors:  Ken Mackie
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

Review 3.  G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.

Authors:  Thomas M Bridges; Craig W Lindsley
Journal:  ACS Chem Biol       Date:  2008-07-25       Impact factor: 5.100

Review 4.  Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders.

Authors:  Clementina Manera; Chiara Arena; Andrea Chicca
Journal:  Recent Pat CNS Drug Discov       Date:  2016

5.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

Review 6.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Authors:  Robin Christensen; Pernelle Kruse Kristensen; Else Marie Bartels; Henning Bliddal; Arne Astrup
Journal:  Lancet       Date:  2007-11-17       Impact factor: 79.321

7.  PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

Authors:  J G Horswill; U Bali; S Shaaban; J F Keily; P Jeevaratnam; A J Babbs; C Reynet; P Wong Kai In
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 8.  Cannabinoid physiology and pharmacology: 30 years of progress.

Authors:  Allyn C Howlett; Christopher S Breivogel; Steven R Childers; Samuel A Deadwyler; Robert E Hampson; Linda J Porrino
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

9.  Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent.

Authors:  Simon Nicolussi; Andrea Chicca; Mark Rau; Sabine Rihs; Michael Soeberdt; Christoph Abels; Jürg Gertsch
Journal:  Biochem Pharmacol       Date:  2014-11-04       Impact factor: 5.858

10.  Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

Authors:  Fabricio A Pamplona; Juliano Ferreira; Octávio Menezes de Lima; Filipe Silveira Duarte; Allisson Freire Bento; Stefânia Forner; Jardel G Villarinho; Luigi Bellocchio; Luigi Bellochio; Carsten T Wotjak; Raissa Lerner; Krisztina Monory; Beat Lutz; Claudio Canetti; Isabelle Matias; João Batista Calixto; Giovanni Marsicano; Marilia Z P Guimarães; Reinaldo N Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

View more
  4 in total

Review 1.  Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.

Authors:  Rachel Dopart; Dai Lu; Aron H Lichtman; Debra A Kendall
Journal:  Drug Metab Rev       Date:  2018-01-21       Impact factor: 4.518

Review 2.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

3.  Structural Optimization of the Diarylurea PSNCBAM-1, an Allosteric Modulator of Cannabinoid Receptor 1.

Authors:  Rachel Dopart; Sri Sujana Immadi; Dai Lu; Debra A Kendall
Journal:  Curr Ther Res Clin Exp       Date:  2019-12-24

Review 4.  Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.

Authors:  Szymon Hryhorowicz; Marta Kaczmarek-Ryś; Angelika Andrzejewska; Klaudia Staszak; Magdalena Hryhorowicz; Aleksandra Korcz; Ryszard Słomski
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.